NCT02282878 The Effect of Dietary Salt Intake on Immune Function in Patients With Multiple Sclerosis Status COMPLETED Phase NA
NCT02280096 Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis Status COMPLETED Phase PHASE2
NCT02274935 Cognitive Motor Interference Rehabilitation in Persons With Multiple Sclerosis Status COMPLETED Phase NA
NCT02269930 Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers Status COMPLETED Phase PHASE1
NCT02259361 Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS Status UNKNOWN Phase PHASE4
NCT02257606 Robot-assisted Training of the Upper Limb in Persons With Multiple Sclerosis: an Randomized Controlled Trial Status COMPLETED Phase NA
NCT02252666 Exploring the Use of Non-invasive Neuromodulation Combined With Exercise in People With Advanced Multiple Sclerosis (MS) Status COMPLETED Phase NA
NCT02239393 Safety and Efficacy of Intravenous Autologous Mesenchymal Stem Cells for MS: a Phase 2 Proof of Concept Study Status COMPLETED Phase PHASE2
NCT02236624 Aerobic Exercise and Flu-like Symptoms Following Interferon Beta 1a Injections in Patients With Multiple Sclerosis? Status COMPLETED Phase NA
NCT02232061 Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks Status COMPLETED Phase PHASE4
NCT02225977 Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya. Status COMPLETED Phase N/A
NCT02220244 Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis Status UNKNOWN Phase PHASE3
NCT02219932 Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis Status COMPLETED Phase PHASE3
NCT02218879 Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS Status TERMINATED Phase N/A
NCT02212886 Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS Status COMPLETED Phase PHASE1/PHASE2